homoharringtonine/fièvre

Le lien est enregistré dans le presse-papiers

Des articlesEssais cliniquesBrevets

Choisissez le type de tri

11 résultats

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Acute myeloid leukemia (AML) is a malignantly clonal and highly heterogeneous disease. Although the treatment of AML has brought promising outcomes for younger patients, prognosis of the elderly remains dismal. Innovative regimens are increasingly necessary to be

Phase I clinical investigation of homoharringtonine.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Homoharringtonine is a cephalotaxine ester derived from Cephalotaxus harringtonia, which is a Chinese evergreen tree. A limited clinical evaluation of this drug in China revealed antileukemic activity, which prompted clinical trials in the United States. We have treated 43 patients with a variety of

Homoharringtonine induces heat protection and facilitates dissociation of heat shock transcription factor and heat shock element complex.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

We investigated the effects of combined treatment with homoharringtonine (HHT) and hyperthermia on cytotoxicity and transcriptional regulation of heat shock genes in human colon carcinoma (HT-29) cells. The drug (100 ng/ml) which inhibited protein synthesis by 93% protected cells from killing at 43

[Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

OBJECTIVE To assess complete remission (CR), the overall survival (OS), event-free survival (EFS) and adverse events of newly diagnosed acute promyelocytic leukemia (APL) with homoharringtonine (HHT) plus ATRA, to evaluate the therapeutic effect by comparing HHT plus ATRA with daunorubicin plus ATRA

[Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

The purpose of this study was to assess the efficacy and toxicity of HAI regimen [(homoharringtonine 2.5 mg/(m(2)×d), days 1 - 7; cytarabine 150 mg/(m(2)×d), days 1 - 7; idarubicin 9 mg/(m(2)×d), days 1 - 7)] for induction treatment of newly diagnosed acute myeloid leukemia (AML) (except acute

Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Five phase II trials of the antitumor agent homoharringtonine were conducted in 80 patients who had advanced solid tumors. The five categories of solid tumors included malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. The starting dose of homoharringtonine was

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Homoharringtonine (HHT) is a plant alkaloid with potent myelosuppressive activity and little toxicity when used in a continuous infusion schedule. The antileukemic efficacy of HHT has been shown in acute myeloid leukemia, but has not been investigated in chronic myelogenous leukemia (CML).

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this

Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

A 77-year-old male was admitted to hospital after complaining of fever and a cough for three days. A diagnosis of multiple myeloma was confirmed following M protein identification and a bone marrow biopsy. The patient received chemotherapy regimens of bortezomib plus dexamethasone, cyclophosphamide,

[Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

A 30 years-old man was administrated with dizziness and fatigue for half month, and the big toe on his left foot got the prolonged bleeding of wound complicated with fever 7 days before the admission. The physical examination (PE) discovered that the case suffered from the anemic appearance, lower

[Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

OBJECTIVE Glivec was approved by Food & Drug Administration (FDA) in May 2001 as a gene target drug for treatment of chronic myeloid leukemia (CML) and showed a good curative effect for patients with chronic myeloid leukemia in chronic phase. But its effectiveness was poor in patients with CML blast

Rejoignez notre
page facebook

Herbal & Natural Medicine

La base de données d'herbes médicinales la plus complète soutenue par la science

Fonctionne en 55 langues
Cures à base de plantes soutenues par la science
Reconnaissance des herbes par image
Carte GPS interactive - étiquetez les herbes sur place (à venir)
Lisez les publications scientifiques liées à votre recherche
Rechercher les herbes médicinales par leurs effets
Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées